Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Agilent, Edico Genome, Alere, and More

NEW YORK (GenomeWeb) – Agilent Technologies this week announced that its board has approved a quarterly dividend of $.13 per share of common stock, payable on Oct. 25 to all shareholders of record as of the close of business on Oct. 3.

Edico Genome announced this week that its DRAGEN Bio-IT Platform is now available on Illumina's BaseSpace Sequence Hub. Users can now run DRAGEN instances to enhance the accuracy and speed of their secondary analysis of next-generation sequencing data, the company said.

Alere this week informed the New York Stock Exchange in writing of its intention to voluntarily delist its Series B convertible perpetual preferred stock from the exchange. The delisting is dependent on the successful completion of Abbott’s $5.3 billion acquisition of Alere.

Alere also this week declared a cash dividend of $3 per share on its Series B convertible perpetual preferred stock, payable on Oct. 16 to shareholders of record at the close of business on Oct. 2.

HTG Molecular Diagnostics this week received continued ISO 13485 certification for its quality management system. The certification was issued by a registrar accredited under the Canadian Medical Device Conformity Assessment System, which is required by regulators in Canada to market in vitro diagnostic products in that country.

Genetic Technologies said this week it is moving to the web to sell its non-hereditary breast cancer testing service. The firm, which announced earlier this year that it was switching to a direct self-pay model from a traditional insurance reimbursement-based payment system, said this week it is moving its commercial program to an e-commerce-based model. Customers will now be able to access the firm's Consumer Initiated Testing platform via the website of Genetic Technologies' US subsidiary, Phenogen Sciences. CIT provides testing with guidance from a remote physician. The company offers its Brevagenplus test for $349.

Computational genomics company GenePeeks and egg donor and surrogate search service Donor Concierge this week announced they have entered into a strategic partnership. Through the partnership, Donor Concierge's customers will have access to GenePeeks' next-generation preconception testing in order to find ideal egg donors or surrogates.

N-of- One said this week that it is incorporating recent Association for Molecular Pathology guidelines on reporting somatic cancer variants with enhanced levels of evidence into its existing curation and reporting solutions.

Interpace Diagnostics Group said this week that it received a letter on Sept. 18 from the Nasdaq stating that the company had regained compliance with a listing rule that states it must maintain three audit committee members on its board of directors.

Labcyte said this week that GSK has joined its consortium with AstraZeneca to combine acoustic liquid dispensing technology from Labcyte with mass spectrometry for use in high throughput small molecule screening and other drug discovery applications. Acoustic liquid dispensing uses sound waves to move minute quantities of liquid, and has been enhanced to generate nano-droplets in a process called Acoustic Mist Ionization. The use of MS through AMI in high throughput applications has the potential to reduce both cost and cycle time in early drug discovery, the company said. With the addition of GSK, the companies have formed a consortium to advance the development of Acoustic-MS for high-throughput chemistry analysis, and biochemical and cell-based assays supporting a range of drug targets. Both pharmaceutical companies will work with multiple prototype instruments and will share their findings with other members of the consortium. Labcyte plans to launch a commercial Acoustic-MS system designed to support a broad range of assays.

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on the GenomeWeb site.